Abdulrahman Katib: Factor XI Inhibitors as the Next Frontier in the Thrombosis Treatment Landscape
Abdulrahman Katib, Internal Medicine and Adult Thrombosis Consultant at King Faisal Specialist Hospital and Research Center, shared on LinkedIn:
“Factor XI inhibitors are quickly becoming one of the most intensely studied drug classes in thrombosis medicine today.
What makes them so exciting is the possibility of achieving meaningful antithrombotic protection while preserving hemostasis — something we have been striving for in anticoagulation for decades.
That said, true clinical efficacy still needs to be firmly established in some of our highest-risk populations, particularly cancer-associated thrombosis (CAT), where thrombosis biology and bleeding risk coexist in a very delicate balance.
On a personal level, I was truly privileged to be part of the MAGNOLIA and ASTER trials.
Being involved in research at this stage — before results are known — is a unique experience. It reminds you that every future guideline, every future practice change, starts with patients, investigators, and teams working together to answer difficult clinical questions.
I am genuinely looking forward to seeing the final publications and understanding where Factor XI inhibition will ultimately position itself in our thrombosis treatment landscape.”
More posts about Abdulrahman Katib.
-
Jun 23, 2026, 23:30Shunsuke Iwano: PMDA Introduces Greater Flexibility for Pediatric Factor VIII and IX Development in Japan
-
Jun 23, 2026, 23:05Rounak Dubey: ISBT Academy Session on Agentic AI
-
Jun 23, 2026, 22:59Mohammed Maher Babiker: When ‘Low Platelets’ aren’t Really Low
-
Jun 23, 2026, 22:49Giovanni Merlino: Why Does Stress Hyperglycemia Worsen Stroke Outcomes?
-
Jun 23, 2026, 22:41Tareq Abadl: Coombs Test – The Key to Detecting Immune-Mediated Hemolysis
-
Jun 23, 2026, 22:32How WFH Impacted the Bleeding Disorders Community in 2025
-
Jun 23, 2026, 22:03Erin VanDyke: A Journey Through VTE Leadership and Healthcare Transformation
-
Jun 23, 2026, 21:19Ahmed Koriesh: Join Us for Future of Stroke Care 2026
-
Jun 23, 2026, 20:30Aladdin Mohammad: Baseline IgG as a Key Predictor of Hypogammaglobulinaemia in AAV